Data describing the effect of DRD4 promoter polymorphisms on promoter activity  by Tei, Shoin et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 7 (2016) 1112–1117S
M
T
H
D
http://d
2352-34
(http://c
DOI
n Corr
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleData describing the effect of DRD4 promoter
polymorphisms on promoter activity
Shoin Tei, Hiroaki Mitsuhashi, Shoichi Ishiura n
Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba,
Meguro-ku, Tokyo, Japana r t i c l e i n f o
Article history:
Received 21 December 2015
Received in revised form
20 March 2016
Accepted 24 March 2016
Available online 1 April 2016x.doi.org/10.1016/j.dib.2016.03.084
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author.
ail address: cishiura@mail.ecc.u-tokyo.ac.jpa b s t r a c t
This data article tested whether polymorphisms within the dopa-
mine D4 receptor (DRD4) gene promoter can lead to differences in
the promoter activity. The variants, a 120-bp variable number
tandem repeat (VNTR), 906 T/C, 809 G/A, 616G/C, and
521C/T, were introduced into the DRD4 promoter and the pro-
moter activity was measured in a neural cell line using the luci-
ferase assay. However, no differences were detected among the
haplotypes investigated, and the in vitro data obtained from our
protocol could not support the involvement of DRD4 promoter
polymorphisms in heritable human traits.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcation Tableubject area Biology
ore speciﬁc sub-
ject areaMolecular biology, Geneticsype of data Table, image, graph
ow data was
acquiredRT-PCR, Luciferase assayata format Raw, analysedvier Inc. This is an open access article under the CC BY license
/j.bbrc.2016.03.140
(S. Ishiura).
EE
D
Fig.
kee
S. Tei et al. / Data in Brief 7 (2016) 1112–1117 1113xperimental
factors1. RT-PCR analysis of D
ping gene GAPDH was aPolymorphisms (120-bp VNTR, rs3758653 for 906 T/C, rs936461 for 809 G/
A, rs747302 for 616 G/C, and rs1800955 for 521 C/T) were introduced into
the promoter sequence of the DRD4 genexperimental
featuresDRD4 expression was detected by RT-PCR using cDNA from SH-SY5Y cells. Fireﬂy
luciferase gene downstream of DRD4 promoter was expressed in SH-SY5Y cells,
and the luciferase activity of each construct was measured 48 h after
transfectionata source
locationUniversity of Tokyo, Japanata accessibility Data supplied with this articleDValue of the data We examined the effect of DRD4 promoter polymorphisms on gene expression in an in vitro
reporter gene experiment.
 This data is useful for characterising the link between heritable mental traits and the
polymorphisms.
 Our data can provide insight into methodology and considerations for investigation of poly-
morphisms in non-coding regions.1. Data
Endogenous dopamine D4 receptor (DRD4) gene expression in SH-SY5Y cells was detected by
RT-PCR using cDNA derived from the cell line (Fig. 1).
To test whether the polymorphisms within the promoter change the promoter activity, luciferase
activity was measured under the inﬂuence of the DRD4 promoter into which polymorphisms were
introduced (Fig. 2 and Table 1). All of the reporter plasmids containing the DRD4 fragment exhibited
signiﬁcantly higher luciferase activity than the control pGL3-Basic, and although every possible
combination of haplotypes was investigated, there were no activity differences among the introduced
mutations in SH-SY5Y cells (Figs. 3 and 4).2. Experimental design, materials and methods
2.1. Construction of reporter plasmid
A DNA fragment spanning 1576 to 1 of the DRD4 promoter region was ampliﬁed from human
genomic DNA with TaKaRa LA Taq (TaKaRa) and inserted into pCR-Blunt (Life Technology). The cloned
sequence was conﬁrmed by Sanger sequencing and shown in Supplementary Fig. 1. Mutations were
introduced using PCR-based site-directed mutagenesis for the four SNPs, and with NotI treatment forDRD4
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Fig. 2. Schematic representation of the DRD4 gene and the reporter construct with the locations of the polymorphisms studied.
The DNA fragment cloned here corresponded to region 1576 to 1 relative to the translation start site, and was the longest
among functional assays on mutated DRD4 promoter;591 to 123 was cloned in Okuyama et al [2], 1389 to 1203 in
D'Souza et al. [3], 668 to 389 in Kreszturi et al. [4] and 1571 to 389 in Kreszturi et al. [5].The putative silencer (dark
grey boxes, 1571 to 800 and 770 to 678) and enhancer (light grey box, 591 to 123) regions are indicated in the
DRD4 gene promoter (white arrow) [1,4]. The 120-bp VNTR is 1.2 kb upstream from the initial codon, and 521C/T is a C/T SNP
at 521 in the promoter region (the description can be applied to the other SNPs). The promoter was cloned upstream of the
ﬁreﬂy luciferase gene, so that luciferase expression was driven by the promoter. pGL3 promoter which contains SV40 promoter
upstream luciferase gene was used as positive control.
S. Tei et al. / Data in Brief 7 (2016) 1112–11171114the VNTR; DNA ligation after NotI treatment converts a 2-repeat allele into a 1-repeat allele because
one NotI recognition site is present within the repeat. The mutated insertion was subcloned into the
XhoI and HindIII sites of pGL3-Promoter Vector (Promega) replacing the original SV40 promoter with
the DRD4 promoter. The primer sequences used for construction are shown in Table 2.2.2. Cell culture and transfection
Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco's Modiﬁed Eagle's Medium
(Sigma-Aldrich) supplemented with 10% foetal bovine serum (Invitrogen) at 37 °C in a humidiﬁed
atmosphere containing 5% CO2. Twenty-four hours before transfection, cells were plated at
4105 cells/well in 96-well plates.
The reporter plasmid (0.2 ng/well) and pRL-TK (0.01 ng/well) were transfected into SH-SY5Y cells
with 0.06 μL/well FuGENE 6 Transfection Reagent (Promega), according to the manufacturer's
protocol.2.3. Luciferase assay
Forty-eight hours after transfection, the luciferase activity was measured in quadruplicate with the
Dual-Glo Luciferase assay System (Promega) using Centro LB960 (Berthold), following the manu-
facturer's instructions. Relative luciferase activity was calculated as the ratio of ﬁreﬂy to Renilla
luciferase activity.2.4. Total RNA isolation and RT-PCR
Total RNA of SH-SY5Y was extracted with GenElute Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich). First-strand cDNA was synthesised from extracted RNA using Prime Script RT Reagent Kit
with gDNA Eraser (Perfect Real Time) (TaKaRa). DRD4mRNA expressionwas detected using TaKaRa LA
Taq, as described [1]. To verify the procedure, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was ampliﬁed as an internal control. The primer sequences used for RT-PCR are shown in Table 2.
Table 1
The constructed haplotypes consisted of 120-bp VNTR and four SNPs of the DRD4 gene.
Reporter
construct
120 bp
VNTR
906 C/T 809 G/A 616 G/C 521 C/T
1R-WT 1 T G G C
1R-521 1 T G G T
1R-616 1 T G C C
1R-809 1 T A G C
1R-906 1 C G G C
2R-WT 2 T G G C
2R-521 2 T G G T
2R-616 2 T G C C
2R-809 2 T A G C
2R-906 2 C G G C
1R-521-616 1 T G C T
1R-521-809 1 T A G T
1R-521-906 1 C G G T
1R-616-809 1 T A C C
1R-616-906 1 C G C C
1R-809-906 1 C A G C
1R-521-616-809 1 T A C T
1R-521-616-906 1 C G C T
1R-521-809-906 1 C A G T
1R-616-809-906 1 C A C C
1R-521-616-809-
906
1 C A C T
2R-521-616 2 T G C T
2R-521-809 2 T A G T
2R-521-906 2 C G G T
2R-616-809 2 T A C C
2R-616-906 2 C G C C
2R-809-906 2 C A G C
2R-521-616-809 2 T A C T
2R-521-616-906 2 C G C T
2R-521-809-906 2 C A G T
2R-616-809-906 2 C A C C
2R-521-616-809-
906
2 C A C T
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Fig. 3. The effect of the polymorphisms on the DRD4 promoter activity. DRD4 promoter activity was measured as the luciferase
activity in SH-SY5Y cells. The relative luciferase activity of pGL3-Basic was deﬁned as 1 and pGL3 promoter was used as positive
control. The assay failed to detect any signiﬁcant differences between haplotypes. Data are expressed as means7SD (n¼5)
(Tukey–Kramer test, **po0.01).
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Fig. 4. The effect of the combined polymorphisms on the DRD4 promoter activity. DRD4 promoter activity was measured as
luciferase activity in SH-SY5Y cells. The relative luciferase activity of pGL3-Basic was deﬁned as 1 and pGL3 promoter was used
as positive control. The assay failed to detect any signiﬁcant differences between haplotypes. Data are expressed as means7SD
(n¼4) (Tukey–Kramer test, **po0.01).
Table 2
Primer sequences and application.
Application Forward Reverse
Ampliﬁcation of DRD4 promoter ACCActcgaGAGGCTGGGCTGGACTCGCCGTTT AAGGaagcttGGCGCGCCCGGGCGG
nThe lower-case letters represent XhoI or HindIII restriction sites.
Nucleotide substitution 916 T4C GAAGAGTCCATAGAACTCTCTGCTGCGCTTTGC GCAAAGCGCAGCAGA-
GAGTTCTATGGACTCTTC
Nucleotide substitution 809 G4A CGAGCCGAACCTACTGTCCGGTCCCG CGGGACCGGACAGTAGGTTCGGCTCG
Nucleotide substitution 616 G4C GCGGGGGCTGAGCACCAGAGGCTGC GCAGCCTCTGGTGCTCAGCCCCCGC
Nucleotide substitution 521 T4C GCGTGGAGGGCGCGCACGAGG CCTCGTGCGCGCCCTCCACGC
nThe underlined letters correspond to each SNP
RT-PCR of DRD4 GCACCGCCTCCATCTTCAACC CGGAACGTGGCCCAGTAGAGC
RT-PCR of GAPDH AAGGCTGAGAACGGGAAGCTTGTCATCAAT TTCCCGTCTAGCTCAGGGAT-
GACCTTGCCC
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